JP2024081650A5 - - Google Patents
Info
- Publication number
- JP2024081650A5 JP2024081650A5 JP2024032974A JP2024032974A JP2024081650A5 JP 2024081650 A5 JP2024081650 A5 JP 2024081650A5 JP 2024032974 A JP2024032974 A JP 2024032974A JP 2024032974 A JP2024032974 A JP 2024032974A JP 2024081650 A5 JP2024081650 A5 JP 2024081650A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- diabetes
- subject
- ezetimibe
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722766P | 2018-08-24 | 2018-08-24 | |
| US62/722,766 | 2018-08-24 | ||
| US201862751404P | 2018-10-26 | 2018-10-26 | |
| US62/751,404 | 2018-10-26 | ||
| PCT/US2019/048184 WO2020041799A1 (en) | 2018-08-24 | 2019-08-26 | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses |
| JP2021510013A JP2021534208A (ja) | 2018-08-24 | 2019-08-26 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510013A Division JP2021534208A (ja) | 2018-08-24 | 2019-08-26 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024081650A JP2024081650A (ja) | 2024-06-18 |
| JP2024081650A5 true JP2024081650A5 (https=) | 2025-10-16 |
Family
ID=69591419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510013A Pending JP2021534208A (ja) | 2018-08-24 | 2019-08-26 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
| JP2024032974A Pending JP2024081650A (ja) | 2018-08-24 | 2024-03-05 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510013A Pending JP2021534208A (ja) | 2018-08-24 | 2019-08-26 | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210322376A1 (https=) |
| EP (1) | EP3841105A4 (https=) |
| JP (2) | JP2021534208A (https=) |
| KR (1) | KR20210079275A (https=) |
| CN (1) | CN113166195A (https=) |
| AU (1) | AU2019325705A1 (https=) |
| BR (1) | BR112021003265A2 (https=) |
| CA (1) | CA3110346A1 (https=) |
| CL (1) | CL2021000444A1 (https=) |
| CO (1) | CO2021003726A2 (https=) |
| IL (1) | IL281016A (https=) |
| MX (1) | MX2021002090A (https=) |
| PH (1) | PH12021550656A1 (https=) |
| SG (1) | SG11202101717WA (https=) |
| WO (1) | WO2020041799A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3267989A4 (en) | 2015-03-13 | 2018-11-07 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| US20210322375A1 (en) * | 2018-08-27 | 2021-10-21 | Esperion Therapeutics, Inc. | Combination drug formulations for treating patients with cardiovascular disease and associated conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000684A1 (es) * | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| CN103239449A (zh) * | 2012-12-26 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法 |
| MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2018148417A1 (en) * | 2017-02-08 | 2018-08-16 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease |
-
2019
- 2019-08-26 MX MX2021002090A patent/MX2021002090A/es unknown
- 2019-08-26 EP EP19852458.9A patent/EP3841105A4/en active Pending
- 2019-08-26 JP JP2021510013A patent/JP2021534208A/ja active Pending
- 2019-08-26 US US17/271,045 patent/US20210322376A1/en active Pending
- 2019-08-26 SG SG11202101717WA patent/SG11202101717WA/en unknown
- 2019-08-26 KR KR1020217008742A patent/KR20210079275A/ko not_active Ceased
- 2019-08-26 CA CA3110346A patent/CA3110346A1/en active Pending
- 2019-08-26 PH PH1/2021/550656A patent/PH12021550656A1/en unknown
- 2019-08-26 WO PCT/US2019/048184 patent/WO2020041799A1/en not_active Ceased
- 2019-08-26 BR BR112021003265-7A patent/BR112021003265A2/pt unknown
- 2019-08-26 AU AU2019325705A patent/AU2019325705A1/en not_active Abandoned
- 2019-08-26 CN CN201980067823.7A patent/CN113166195A/zh active Pending
-
2021
- 2021-02-22 CL CL2021000444A patent/CL2021000444A1/es unknown
- 2021-02-22 IL IL281016A patent/IL281016A/en unknown
- 2021-03-24 CO CONC2021/0003726A patent/CO2021003726A2/es unknown
-
2024
- 2024-03-05 JP JP2024032974A patent/JP2024081650A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024081650A5 (https=) | ||
| JP7629049B2 (ja) | 貧血治療のための組成物及び方法 | |
| JP2021515772A5 (https=) | ||
| AU2026200681A1 (en) | Treatment for fibrosis | |
| Cho et al. | Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity | |
| CN106062003A (zh) | 用于与pcsk9抑制剂一起使用的给药方案 | |
| JP7617898B2 (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| Yap et al. | Long-term results of triple immunosuppression with tacrolimus added to mycophenolate and corticosteroids in the treatment of lupus nephritis | |
| JP2023501457A5 (https=) | ||
| US20190175619A1 (en) | Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| US20070274977A1 (en) | Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injections of PEG-Uricase | |
| JP2021534208A5 (https=) | ||
| JP2024081650A (ja) | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 | |
| JP2023543133A5 (https=) | ||
| WO2011150067A1 (en) | Treatment of blood lipid abnormalities and other conditions | |
| WO2025007946A1 (zh) | 治疗前列腺癌的方法 | |
| AU2005264301B2 (en) | Therapeutic or preventive drug for diabetes, obesity, or arteriosclerosis | |
| RU2021107420A (ru) | Способы снижения риска сахарного диабета у больных, подлежащих лечению от заболеваний, связанных с высоким содержанием холестерина | |
| US20060030623A1 (en) | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis | |
| CN117100748A (zh) | 罗沙司他在制备治疗慢性肾脏病高脂血症药物中的应用 | |
| Leskovar et al. | Pregnancy in Familial Chylomicronemia Syndrome: Plasmapheresis as Therapeutic Approach | |
| AU2019376907B2 (en) | Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients | |
| Imro'ati et al. | The Management Problems of Patient with Chronic Hepatitis B Infection and Its Reactivation | |
| TW202517250A (zh) | Ｌｐ（ａ）干擾劑化合物之治療用途及劑量 | |
| HK40066537B (en) | Improved treatment using eyp001 |